Table 5.
Comparison of PFS between nivolumab and irinotecan according to response
| Response | No of patients median PFS (month) (95% CI) |
HR (95% CI) |
P value | |
| Nivolumab | Irinotecan | |||
| All | N=34 1.4 (0.8 to 1.8) |
N=66 2.2 (1.9 to 3.0) |
1.1 (0.7 to 1.6) | 0.802 |
| Non-PD (PR+SD) | N=13 6.4 (2.4 to 14.8) |
N=23 4.8 (4.1 to 6.4) |
0.6 (0.3 to 1.2) | 0.155 |
| PR | N=2 14.8 (14.8 to NA) |
N=4 11.0 (8.1 to NA) |
0.3 (0.03 to 2.4) | 0.229 |
| SD | N=11 5.5 (1.4 to 11.5) |
N=19 4.5 (3.9 to 5.3) |
0.6 (0.2 to 1.3) |
0.188 |
| PD | N=21 0.8 (0.6 to 1.4) |
N=43 1.9 (1.6 to 2.1) |
4.3 (2.3 to 8.2) | <0.0001 |
| PD other than HPD | N=11 0.8 (0.5 to 1.5) |
N=34 1.8 (1.4 to 2.1) |
3.7 (1.7 to 8.0) | 0.00098 |
| HPD | N=10 0.9 (0.3 to 1.4) |
N=9 2.1 (0.5 to 2.3) |
8.7 (1.8 to 41.8) | 0.00671 |
HPD, hyperprogressive disease; PD, progressive disease; PFS, progression-free survival;PR, partial response;SD, stable disease.